EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 27-Oct-2026 21:16 ET (28-Oct-2026 01:16 GMT/UTC)

7-Jul-2026

Turning up the heat on cancer: UTEP physicists discover better nanoparticles for future therapy

University of Texas at El Paso
Peer-Reviewed Publication

Physicists at The University of Texas at El Paso and Alexandria University in Egypt describe how to better harness heat against cancer using magnetic nanoparticles made from manganese ferrite.

Journal: Scientific Reports

7-Jul-2026

Scientists uncover why some patients with rare leukemia may not benefit from approved targeted therapy

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and Drug Administration-approved treatment for this disease.

Journal: Leukemia

7-Jul-2026

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7-Jul-2026

Common thyroid hormone may help prevent brain tumor relapse in children, says study

Temple University Health System
Peer-Reviewed Publication

Fox Chase Cancer Center researchers found that adding an FDA-approved thyroid hormone after chemotherapy helped prevent tumor regrowth in laboratory and animal studies. This approach is now being tested in a national pediatric clinical trial for medulloblastoma.

Journal: Molecular Therapy Oncology

7-Jul-2026

HonorHealth Research Institute is among first in the nation to expand access to new drug that doubles survival of pancreatic cancer patients

HonorHealth Research Institute
Business Announcement

Under an FDA ruling that expands access to clinical trials, HonorHealth Research Institute is one of the first in the nation to offer a new drug, Daraxonrasib, that based on early data nearly doubles the average survival time of patients with pancreatic cancer.

7-Jul-2026

Adaptor proteins emerge as key regulators of tumor-associated macrophages in cancer

Impact Journals LLC
Peer-Reviewed Publication

BUFFALO, NY — July 7, 2026 — A new review was published in Volume 13 of Oncoscience on May 22, 2026, titled “Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression.”

Journal: Oncoscience

7-Jul-2026

Damon Runyon Cancer Research Foundation invests nearly $1.4 million to support physician-scientists

Damon Runyon Cancer Research Foundation
Grant and Award Announcement

Three exceptional young clinicians with novel ideas about cancer treatment have been named the 2026 recipients of the Damon Runyon Physician-Scientist Training Award, providing physicians who have completed clinical specialty fellowship training with the opportunity to become leaders in translational and clinical research.

7-Jul-2026

Wiley launches Advanced Immunology to deepen understanding of the immune system in health and disease

Wiley
Business Announcement

Wiley today announces the launch of Advanced Immunology, a new open access journal designed to connect basic science and clinical discovery across the immune system.

7-Jul-2026

Study from Umeå paves the way for a new drug against metastatic prostate cancer

Umea University
Peer-Reviewed Publication

A new cancer drug may be able to inhibit both tumour growth and the spread of aggressive prostate cancer. This is shown in a study conducted by researchers at Umeå University together with international collaborators, published in the scientific journal Signal Transduction and Targeted Therapy.

Journal: Signal Transduction and Targeted Therapy

7-Jul-2026

One in five relatives of breast and ovarian cancer patients in Estonia carry dangerous cancer-linked genes, study shows

Frontiers
Peer-Reviewed Publication

Testing can reveal whether you carry a genetic variant that increases your chance of developing breast and ovarian cancers, allowing patients to take measures to catch and treat cancer early. Some even choose preventive procedures, like Angelina Jolie, who underwent a mastectomy after learning she carried a pathogenic variant of BRCA1. But lack of testing means many people don’t know they could be at heightened risk. Now a new study published in Frontiers in Genetics shows that 19.7% of breast and ovarian cancer patients’ family members in Estonia carry potentially dangerous genetic variants. This included 34% of men tested and a high proportion of patients too young to have received regular screening.

Journal: Frontiers in Genetics
Funder: Estonian Research Council, Estonian Research Council